IMDZ Snapped Up NVRO Falls On Dim Outlook OPNT Ceases Bulimia Nervosa Trial

IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial

23:57 EST 21 Feb 2019 | RTTNews

Today's Daily Dose brings you news about Exact Sciences' better-than-expected Q4 financial results; Merck's acquisition of Immune Design; Nevro's lackluster revenue outlook; Opiant Pharma' s disappointing Bulimia Nervosa study results; and near-term catalyst of Zosano Pharma.

IMDZ Snapped Up NVRO Falls On Dim Outlook OPNT Ceases Bulimia Nervosa Trial

IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial

More From BioPortfolio on "IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial"